GlassScriptPhysician profile
Anselmo Garcia
NPI 1679791248
$5,580.91
in general payments reported to CMS, 2019-2025
40 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $148 · 2021: $152 · 2022: $511 · 2023: $1,113 · 2024: $1,008 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,459 · Travel and Lodging: $461 · Education: $67.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.17 |
| Travel and Lodging | $460.80 |
| Education | $67.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,138.58 | 2022-2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $512.71 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $358.61 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.96 | 2019-2025 | Ofev |
| Genzyme Corporation | $342.98 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $312.71 | 2019-2025 | Zerbaxa, Recarbrio, Keytruda |
| Regeneron Healthcare Solutions, INC. | $271.64 | 2024-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $251.60 | 2019-2025 | Opsumit, Uptravi |
| Pulmonx Corporation | $226.20 | 2024-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Electromed, INC. | $219.81 | 2019-2025 | Smartvest |
| Baxter Healthcare | $150.83 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $142.81 | 2024-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $137.82 | 2019-2025 | Xolair |
| Sunovion Pharmaceuticals INC. | $137.22 | 2019-2020 | |
| Mylan Specialty L.P. | $133.14 | 2019-2024 | Yupelri |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anselmo Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.